Literature DB >> 21677447

Conditional survival of all primary brain tumor patients by age, behavior, and histology.

Kimberly R Porter1, Bridget J McCarthy, Michael L Berbaum, Faith G Davis.   

Abstract

BACKGROUND: Survival statistics commonly reflect survival from the time of diagnosis but do not take into account survival already achieved after a diagnosis. The objective of this study was to provide conditional survival estimates for brain tumor patients as a more accurate measure of survival for those who have already survived for a specified amount of time after diagnosis.
METHODS: Data on primary malignant and nonmalignant brain tumor cases diagnosed from 1985-2005 from selected SEER state cancer registries were obtained. Relative survival up to 15 years postdiagnosis and varying relative conditional survival rates were computed using the life-table method.
RESULTS: The overall 1-year relative survival estimate derived from time of diagnosis was 67.8% compared to the 6-month relative conditional survival rate of 85.7% for 6-month survivors (the probability of surviving to 1 year given survival to 6 months). The 10-year overall relative survival rate was 49.5% from time of diagnosis compared to the 8-year relative conditional survival rate of 79.2% for 2-year survivors. Conditional survival estimates and standard survival estimates varied by histology, behavior, and age at diagnosis. The 5-year relative survival estimate derived from time of diagnosis for glioblastoma was 3.6% compared to the 3-year relative conditional survival rate of 36.4% for 2-year survivors. For most nonmalignant tumors, the difference between relative survival and the corresponding conditional survival estimates were minimal. Older age groups had greater numeric gains in survival but lower conditional survival estimates than other age groups. Similar findings were seen for other conditional survival intervals.
CONCLUSIONS: Conditional survival is a useful disease surveillance measure for clinicians and brain tumor survivors to provide them with better 'real-time' estimates and hope.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21677447      PMCID: PMC3665939          DOI: 10.1159/000327752

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  6 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Supratentorial low-grade gliomas in older patients.

Authors:  G Kaloshi; D Psimaras; K Mokhtari; C Dehais; C Houillier; Y Marie; F Laigle-Donadey; S Taillibert; R Guillevin; N Martin-Duverneuil; M Sanson; K Hoang-Xuan; J-Y Delattre
Journal:  Neurology       Date:  2009-11-11       Impact factor: 9.910

3.  Conditional survival of 56,268 patients with breast cancer.

Authors:  D E Henson; L A Ries; M T Carriaga
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

4.  On the estimation of survival.

Authors:  D E Henson; L A Ries
Journal:  Semin Surg Oncol       Date:  1994 Jan-Feb

5.  The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data.

Authors:  F G Davis; B J McCarthy; S Freels; V Kupelian; M L Bondy
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

6.  The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme.

Authors:  C L Lin; A S Lieu; K S Lee; Y H C Yang; T H Kuo; M H Hung; J K Loh; C P Yen; C Z Chang; S L Howng; S L Hwang
Journal:  Surg Neurol       Date:  2003-11
  6 in total
  12 in total

Review 1.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

2.  Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008.

Authors:  Y Yuan; J Ross; Q Shi; F G Davis
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

3.  Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.

Authors:  Martin Connock; Peter Auguste; Claude Dussart; Jacques Guyotat; Xavier Armoiry
Journal:  J Neurooncol       Date:  2019-05-24       Impact factor: 4.130

4.  Prognostic value of age in neurological cancer: an analysis of 22,393 cases from the SEER database.

Authors:  Minjie Tian; Donglin Zhu; Daowen Chen; Xiaoli Huo; Jianqing Ge; Jie Lu; Li Zhang; Jingping Shi
Journal:  Tumour Biol       Date:  2015-05-27

5.  Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012.

Authors:  Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-04-19       Impact factor: 4.130

Review 6.  Epidemiologic and molecular prognostic review of glioblastoma.

Authors:  Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-22       Impact factor: 4.254

7.  The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma.

Authors:  Wenli Liu; Aiham Qdaisat; Jason Yeung; Gabriel Lopez; Jeffrey Weinberg; Shouhao Zhou; Lorenzo Cohen; Eduardo Bruera; Sai-Ching J Yeung
Journal:  Oncologist       Date:  2018-07-26

8.  Pro-necrotic Activity of Cationic Mastoparan Peptides in Human Glioblastoma Multiforme Cells Via Membranolytic Action.

Authors:  Annielle Mendes Brito da Silva; Laíz Costa Silva-Gonçalves; Fernando Augusto Oliveira; Manoel Arcisio-Miranda
Journal:  Mol Neurobiol       Date:  2017-09-30       Impact factor: 5.590

9.  Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Authors:  Gregory F Guzauskas; Marc Salzberg; Bruce Cm Wang
Journal:  CNS Oncol       Date:  2018-08-20

10.  Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.

Authors:  Minyong Kang; Hyung Suk Kim; Chang Wook Jeong; Choel Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Sci Rep       Date:  2015-07-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.